Free Trial

Arvinas (ARVN) Competitors

Arvinas logo
$7.47 -0.01 (-0.13%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$7.44 -0.04 (-0.47%)
As of 06/18/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARVN vs. DNLI, TWST, VCEL, KNSA, AGIO, SRPT, RXRX, APGE, IDYA, and INDV

Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals (KNSA), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), IDEAYA Biosciences (IDYA), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

Arvinas vs. Its Competitors

Arvinas (NASDAQ:ARVN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Denali Therapeutics received 267 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 68.76% of users gave Denali Therapeutics an outperform vote while only 65.18% of users gave Arvinas an outperform vote.

CompanyUnderperformOutperform
ArvinasOutperform Votes
204
65.18%
Underperform Votes
109
34.82%
Denali TherapeuticsOutperform Votes
471
68.76%
Underperform Votes
214
31.24%

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 4.7% of Arvinas shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arvinas has higher earnings, but lower revenue than Denali Therapeutics. Arvinas is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$263.40M2.07-$198.90M-$0.66-11.32
Denali Therapeutics$330.53M6.19-$422.77M-$2.67-5.28

Arvinas currently has a consensus price target of $20.29, indicating a potential upside of 171.61%. Denali Therapeutics has a consensus price target of $33.71, indicating a potential upside of 139.28%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
0 Sell rating(s)
10 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.55
Denali Therapeutics
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.06

In the previous week, Arvinas had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Arvinas and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.58 beat Arvinas' score of 0.97 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Arvinas has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Denali Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-10.92% -7.74% -4.11%
Denali Therapeutics N/A -35.90%-32.41%

Summary

Denali Therapeutics beats Arvinas on 11 of the 19 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasMED IndustryMedical SectorNASDAQ Exchange
Market Cap$545.24M$2.82B$5.37B$8.57B
Dividend YieldN/A2.67%5.34%4.21%
P/E Ratio-11.3220.9725.3719.22
Price / Sales2.07294.63411.51110.52
Price / CashN/A42.7935.3655.76
Price / Book0.917.487.856.22
Net Income-$198.90M-$55.16M$3.15B$249.15M
7 Day Performance-1.32%-3.70%-2.11%-1.04%
1 Month Performance14.40%6.36%3.71%2.49%
1 Year Performance-69.90%-0.44%37.99%15.34%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARVN
Arvinas
3.7506 of 5 stars
$7.47
-0.1%
$20.29
+171.6%
-69.9%$545.24M$263.40M-11.32420
DNLI
Denali Therapeutics
4.3679 of 5 stars
$14.62
+0.5%
$33.71
+130.6%
-31.7%$2.12B$330.53M-5.30430Positive News
TWST
Twist Bioscience
4.2266 of 5 stars
$35.04
+4.5%
$50.40
+43.8%
-29.0%$2.10B$347.68M-10.37990
VCEL
Vericel
2.3458 of 5 stars
$41.59
-2.5%
$61.14
+47.0%
-3.7%$2.09B$238.54M693.28300Analyst Forecast
KNSA
Kiniksa Pharmaceuticals
3.2181 of 5 stars
$28.41
+0.4%
$38.80
+36.6%
+53.5%$2.07B$481.17M-202.91220Insider Trade
AGIO
Agios Pharmaceuticals
3.839 of 5 stars
$35.75
+4.2%
$58.60
+63.9%
-16.6%$2.07B$37.04M3.15390
SRPT
Sarepta Therapeutics
4.5569 of 5 stars
$20.94
-42.1%
$99.35
+374.4%
-82.3%$2.06B$2.23B16.75840Trending News
Analyst Forecast
Options Volume
Gap Down
High Trading Volume
RXRX
Recursion Pharmaceuticals
2.0075 of 5 stars
$5.00
+1.6%
$7.00
+40.0%
-47.3%$2.03B$59.82M-3.27400Analyst Forecast
APGE
Apogee Therapeutics
2.3943 of 5 stars
$42.61
-4.2%
$94.60
+122.0%
+13.2%$1.96BN/A-17.6191
IDYA
IDEAYA Biosciences
3.6502 of 5 stars
$22.39
+0.9%
$54.27
+142.4%
-41.3%$1.96B$7M-6.7880
INDV
Indivior
1.9596 of 5 stars
$14.18
+2.1%
$15.00
+5.8%
-12.4%$1.96B$1.17B-40.511,164

Related Companies and Tools


This page (NASDAQ:ARVN) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners